

**What is claimed is:**

- 5 1. A method of inhibiting TACI activity, BCMA activity, or both in a mammal, which comprises administering a specific binding partner for APRIL, wherein the specific binding partner comprises
- a. the consensus region of TACI (SEQ ID NO: 16);
  - b. the consensus region of BCMA (SEQ ID NO: 7);
  - c. the TACI/BCMA extracellular consensus sequence (SEQ ID
- 10 NO: 13);
- but does not comprise the extracellular region of TACI (SEQ ID NO: 15) or the extracellular region of BCMA (SEQ ID NO: 6).
- 15 2. The method of Claim 1, further comprising administering a specific binding partner for AGP-3.
3. A method of treating B-cell lymphoproliferative disorders, which comprises administering a therapeutic agent comprising a specific binding partner selected from:
- a. the consensus region of TACI (SEQ ID NO: 16);
  - b. the consensus region of BCMA (SEQ ID NO: 7); or
  - c. the TACI/BCMA extracellular consensus sequence (SEQ ID
- 20 NO: 13)
- but not comprising the extracellular region of TACI (SEQ ID NO: 15) or the extracellular region of BCMA (SEQ ID NO: 6)..
- 25 4. A method of treating T-cell lymphoproliferative disorders, which comprises administering a therapeutic agent comprising a specific binding partner selected from selected from:
- a. the consensus region of TACI (SEQ ID NO: 16);
  - b. the consensus region of BCMA (SEQ ID NO: 7); or
  - c. the TACI/BCMA extracellular consensus sequence (SEQ ID
- 30 NO: 13)

but not comprising the extracellular region of TACI (SEQ ID NO: 15)  
or the extracellular region of BCMA (SEQ ID NO: 6)..

5. A method of treating one or more solid tumors, which comprises administering a therapeutic agent comprising a specific binding  
5 partner selected from:

- the consensus region of TACI (SEQ ID NO: 16);
- the consensus region of BCMA (SEQ ID NO: 7); or
- the TACI/BCMA extracellular consensus sequence (SEQ ID  
NO: 13)

10 but not comprising the extracellular region of TACI (SEQ ID NO: 15)  
or the extracellular region of BCMA (SEQ ID NO: 6).

- The method of Claim 5, wherein the tumor is selected from lung,  
gastrointestinal, pancreatic and prostate
- The method of any of Claims 1, 3, 4, or 5, wherein the specific binding  
15 partner is comprised within a molecule of the formula



wherein:

F<sup>1</sup> is a vehicle;

20 X<sup>1</sup> and X<sup>2</sup> are each independently selected from -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-  
(L<sup>3</sup>)<sub>d</sub>-P<sup>2</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>3</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>, and -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>3</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>-(L<sup>4</sup>)<sub>f</sub>-P<sup>4</sup>  
at least one of P<sup>1</sup>, P<sup>2</sup>, P<sup>3</sup>, and P<sup>4</sup> is the ;

L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup>, and L<sup>4</sup> are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at  
least one of a and b is 1.

- 25 8. The method of Claim 7, wherein the molecule comprises a structure of  
the formulae




or



9. The method of Claim 7, wherein the molecule comprises a structure of the formula



10. The method of Claim 7, wherein the molecule comprises a structure of the formula



wherein one of  $P^1$  and  $P^2$  is the consensus region of TACI (SEQ ID NO: 16) and the other is the consensus region for BCMA (SEQ ID NO: 7).

11. The method of Claim 10, wherein the vehicle is an Fc domain.

12. The method of any of Claims 1, 3, 4, or 5, wherein the specific binding partner replaces a CDR region within an antibody molecule.

13. A composition of matter of the formula



wherein:

- 15  $F^1$  is a vehicle;  
 $X^1$  and  $X^2$  are each independently selected from  $-(L^1)_c-P^1$ ,  $-(L^1)_c-P^1-(L^2)_d-P^2$ ,  $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$ , and  $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$   
 $P^1$ ,  $P^2$ ,  $P^3$ , and  $P^4$  are each independently  
 20 a. the consensus region of TACI (SEQ ID NO: 16);  
 b. the consensus region of BCMA (SEQ ID NO: 7); or  
 c. the TACI/BCMA extracellular consensus sequence (SEQ ID NO: 13)  
 but not the extracellular region of TACI (SEQ ID NO: 15) or  
 25 the extracellular region of BCMA (SEQ ID NO: 6).; and  
 a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

14. The composition of matter of Claim 13 of the formulae



A-686A


or



15. The composition of matter of Claim 14 of the formula



5 16. The composition of matter of Claim 14 of the formula



wherein one of  $P^1$  and  $P^2$  is a specific binding partner for TACI and the other is a specific binding partner for BCMA.

10 17. The composition of matter of Claim 16, wherein the vehicle is an Fc domain.